Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Secondary SBP Prophylaxis is associated with a higher rate of non-SBP infections in Two US-based National Cirrhosis Cohorts

Silvey S, Patel N, O'Leary JG, Jakab SS, Patton H, Rogal S, Markley JD, Cheung R, Patel A, Morgan TR, Bajaj JS. Secondary SBP Prophylaxis[...]

Sex-dependent alterations of colonic epithelial permeability: relevance to irritable bowel syndrome

Larauche M, Mahurkar-Joshi S, Biraud M, Ju T, Mayer EA, Chang L. Sex-dependent alterations of colonic epithelial permeability: relevance to irritable bowel syndrome. Front Physiol.[...]

Optimizing Bowel Preparation Quality for Colonoscopy: Consensus Recommendations by the US Multi-Society Task Force on Colorectal Cancer

Jacobson BC, Anderson JC, Burke CA, Dominitz JA, Gross SA, May FP, Patel SG, Shaukat A, Robertson DJ. Optimizing Bowel Preparation Quality for Colonoscopy: Consensus[...]